Patents Assigned to Ablynx N.V.
  • Patent number: 10875918
    Abstract: The present invention relates to amino acid sequences and polypeptides binding to the P2X7 receptor. In particular, the present invention relates to improved heavy-chain immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVD's”) binding to the P2X7 receptor, as well as to proteins, polypeptides and other constructs, compounds, molecules or 5 chemical entities that comprise such ISVD's.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: December 29, 2020
    Assignee: Ablynx N.V.
    Inventors: Marie-Ange Buyse, Catelijne Stortelers
  • Publication number: 20200392214
    Abstract: The present invention relates to an improved method for the manufacture of immunoglobulin single variable domains. More specifically, the present invention relates to a method of producing immunoglobulin single variable domains in which the proportion of carbamylated variants is strongly reduced or absent and to improved immunoglobulin single variable domains obtainable by methods of the present invention.
    Type: Application
    Filed: August 2, 2019
    Publication date: December 17, 2020
    Applicant: Ablynx N.V.
    Inventors: Ann Brige, Bart Walcarius, Yves Meyvis, Mauro Sergi
  • Publication number: 20200392512
    Abstract: The invention provides improved nucleotide sequences and nucleic acids that encode glycine serine linkers and that use an excess of GGA, GGG, and GGT/GGU codons to encode the glycine residues. The invention further relates to nucleotide sequences and nucleic acids that encode (fusion) proteins and polypeptides comprising glycine serine linkers, which nucleotide sequences and nucleic acids comprise such improved nucleotide sequences and nucleic acids of the invention.
    Type: Application
    Filed: February 26, 2019
    Publication date: December 17, 2020
    Applicant: Ablynx N.V.
    Inventors: Veronique De Brabandere, Ann Brige, Patrick Stanssens, Pieter-Jan De Bock, Tom Merchiers, Antonin De Fougerolles
  • Patent number: 10858418
    Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: December 8, 2020
    Assignee: Ablynx N.V.
    Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
  • Patent number: 10858445
    Abstract: The present invention is based on the finding that administration of polypeptides comprising at least one Immunoglobulin single variable domains against vWF to human TTP patients provides a significant decrease in the time to response. The invention provides a polypeptide comprising at least one immunoglobulin single variable domain (ISVD) against von Willebrand Factor (vWF) for use in treating a vWF-related disease in a human in need thereof. The invention further relates to dosage unit forms, kits and medical uses for treating TTP.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: December 8, 2020
    Assignee: Ablynx N.V.
    Inventor: Christian Duby
  • Patent number: 10844123
    Abstract: The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: November 24, 2020
    Assignee: Ablynx N.V.
    Inventors: Guy Hermans, Peter Verheesen, Edward Dolk, Hendricus Renerus Jacobus Mattheus Hoogenboom, Michael John Scott Saunders, Hans De Haard, Renee de Bruin
  • Patent number: 10822425
    Abstract: The present invention relates to immunoglobulin single variable domain sequences that are directed against (as defined herein) OX40L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such immunoglobulin single variable domain sequences. In particular these immunoglobulin single variable domain sequences can block binding of OX40L to OX40. The immunoglobulin single variable domains, compounds and constructs can be used for prophylactic, therapeutic or diagnostic purposes, such as for the treatment of inflammatory disease and/or disorder such as e.g. asthma, allergic asthma, chronic colitis, Crohn's disease, inflammatory bowel disease, and/or arthrosclerosis.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: November 3, 2020
    Assignee: Ablynx N.V.
    Inventors: Frank Verdonck, Sigrid Cornelis, Stephanie Staelens
  • Publication number: 20200325221
    Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).
    Type: Application
    Filed: March 19, 2020
    Publication date: October 15, 2020
    Applicant: Ablynx N.V.
    Inventors: Judith Baumeister, Marie-Paule Lucienne Amanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
  • Publication number: 20200283509
    Abstract: The present invention relates to amino acid sequences binding to serum albumin. In particular, the present invention relates to improved immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVD's”), and more in particular improved heavy-chain immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVD's”) binding to serum albumin, as well as to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise such improved serum albumin binders.
    Type: Application
    Filed: November 17, 2016
    Publication date: September 10, 2020
    Applicant: Ablynx N.V.
    Inventor: Marie-Ange Buyse
  • Publication number: 20200231662
    Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).
    Type: Application
    Filed: November 26, 2019
    Publication date: July 23, 2020
    Applicant: Ablynx N.V.
    Inventors: Marie-Ange Buyse, Carlo Boutton
  • Publication number: 20200216532
    Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).
    Type: Application
    Filed: March 18, 2020
    Publication date: July 9, 2020
    Applicant: Ablynx N.V.
    Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
  • Publication number: 20200190217
    Abstract: Polypeptides are provided that are capable of significantly inhibiting and/or neutralizing P. aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the “first” immunoglobulin single variable domain and the “second” immunoglobulin single variable domain have different paratopes.
    Type: Application
    Filed: July 17, 2018
    Publication date: June 18, 2020
    Applicant: Ablynx N.V.
    Inventors: Evelyn De Tavernier, Ann Union, Bruno Dombrecht, Guy Hermans, Erika Morizzo
  • Publication number: 20200157216
    Abstract: Polypeptides are provided that bind CD123 on a target cell and the constant domain of TCR on a T cell. The polypeptides can be used in methods for treatment of CD123 associated cancers or inflammatory conditions.
    Type: Application
    Filed: November 16, 2017
    Publication date: May 21, 2020
    Applicant: Ablynx N.V.
    Inventors: Diane Van Hoorick, Annelies Roobrouck, Catelijne Stortelers, João Vieira, Edward McGowan
  • Publication number: 20200140532
    Abstract: The present invention relates to immunoglobulins that specifically bind Aggrecan and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Aggrecan.
    Type: Application
    Filed: June 4, 2018
    Publication date: May 7, 2020
    Applicant: Ablynx N.V.
    Inventors: Soren Steffensen, Gerald Beste, Guy Hermans, Hans Gühring, Christoph Ladel, Lars Toleikis
  • Publication number: 20200123233
    Abstract: The present invention relates in part to amino acid sequences that are directed against and/or that can specifically bind to an envelope protein of a virus, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: August 1, 2019
    Publication date: April 23, 2020
    Applicant: Ablynx N.V.
    Inventors: Catelijne Stortelers, Peter Vanlandschoot, Erik Depla, Jose Melero
  • Patent number: 10618964
    Abstract: The present invention relates to amino acid sequences that are directed against/and or that can specifically bind (as defined herein) Interleukin-6 Receptor (IL-6R), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. In a specific aspect, the present invention provides amino acid sequences and polypeptides that are capable of binding to two or more different antigenic determinants, epitopes, parts, domains of IL-6R, also referred to as “multiparatopic” (such as e.g. “biparatopic” or “triparatopic”, etc.) amino acid sequences and polypeptides.
    Type: Grant
    Filed: April 12, 2010
    Date of Patent: April 14, 2020
    Assignee: Ablynx N.V.
    Inventors: Veerle Compernolle, Francis Descamps
  • Patent number: 10618966
    Abstract: The invention relates to amino acid sequences that are directed against and/or that can specifically bind to IL-6 receptor, compounds or constructs that comprise the amino acid sequence, nucleic acids that encode the amino acid sequences, compounds or constructs, pharmaceutical compositions comprising the amino acid sequences, compounds or constructs as well as methods for the prevention and/or treatment of diseases and disorders associated with IL-6 receptor.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: April 14, 2020
    Assignee: Ablynx N.V.
    Inventors: Joost Alexander Kolkman, Els Anna Alice Beirnaert
  • Publication number: 20200079844
    Abstract: The present invention relates to improved Nanobodies™ against Tumor Necrosis Factor-alpha (TNF-alpha), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions comprising such Nanobodies, polypeptides, nucleic acids or host cells; and to uses of such Nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes.
    Type: Application
    Filed: May 28, 2019
    Publication date: March 12, 2020
    Applicant: Ablynx N.V.
    Inventor: Els Anna Alice Beirnaert
  • Publication number: 20200062834
    Abstract: The present invention relates to an improved method for the manufacture of immunoglobulin single variable domains. More specifically, the present invention relates to a method of producing immunoglobulin single variable domains in which the proportion of carbamylated variants is strongly reduced or absent and to improved immunoglobulin single variable domains obtainable by methods of the present invention.
    Type: Application
    Filed: August 2, 2019
    Publication date: February 27, 2020
    Applicant: Ablynx N.V.
    Inventors: Ann Brige, Bart Walcarius, Yves Meyvis, Mauro Sergi
  • Patent number: 10561805
    Abstract: Methods are provided for the treatment of RSV infections in young children. More specifically, methods are provided wherein polypeptides that bind F protein of hRSV and that neutralize RSV infection are administered to the lungs of young children at specific dose regimens.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: February 18, 2020
    Assignees: ABLYNX N.V., VECTURA GMBH
    Inventors: Koen Allosery, Erik Depla, Martin Huber, Tobias Kolb, Bernhard Müllinger, Massimiliano Germani, Juliane Schick, Maria-Laura Sargentini